Catherine has earned her reputation as a biopharmaceutical thought leader and gained the trust of C-Suite and Board Members of life science companies having spent more than 25 years engaging with them. Her perspective is differentiated as a result of her diverse experience, having been a public equity investor for one of the world’s largest asset managers, an industry executive, a top-ranked sell-side analyst, and a clinician at a large university medical center. These roles gave her relevant experience for our Healthcare Practice in that she identified and negotiated innovative business development transactions, vetted public offerings and M&A deals, debated and help define corporate strategy, determined valuation and shaped governance policy and practice, which influenced institutional investments and shareholder returns.

Ms. Arnold’s recent life science transactions and advisory include:

• The $40bn acquisition by AstraZeneca of Alexion
• $12.5bn sale of Biohaven to Pfizer with simultaneous spin of neuroscience assets into a new publicly traded company
• $11.5bn sale of Acceleron to Merck
• $6.7bn acquisition of Arena Pharmaceuticals by Pfizer
• Sanofi’s strategic review and bid for Horizon Therapeutics, ultimately acquired by Amgen for $28bn
• Pfizer’s spin out of select autoimmune assets

Prior to joining Centerview, Catherine served as Managing Director, Portfolio Manager and Biopharmaceuticals Global Industry Analyst at Wellington Management in Boston, Massachusetts. In this role she regularly engaged with healthcare executives and boards on strategy, industry dynamics, capital markets and science. While at Wellington, she served as an active member of the firm’s Investment Stewardship Committee, charged with recommending philosophy, process and action on firm ESG matters. Prior to Wellington, Catherine spent more than a decade as a top-rated sell-side analyst at Credit Suisse and Sanford C. Bernstein & Co., covering the biopharmaceutical sector. Earlier in her career, Ms. Arnold served as the Director of Business Development and Strategic Planning at Hoffman-La Roche Pharmaceuticals and as a Senior Associate in the Biopharma Management Consulting Practice at Booz Allen Hamilton. Ms. Arnold has served on the Advisory Board for the FDA Modernization Task Force of The Center for Health Transformation, a member of the Health Forum of the Aspen Institute and was a Director of the National Board of the Cancer Support Community. She has contributed to Columbia Business School’s Healthcare and Pharmaceutical Management Program and has served as a Series Guest Lecturer at Harvard Business School.